Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
reactogenicity was higher in children receiving whole cell pertussis vaccines concurrently.
reaktogeensus oli kõrgem lastel, kes said samaaegselt täisrakulist läkaköha vaktsiini.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
regardless of age, reactogenicity was higher after the first dose than after the second vaccination.
vanusest olenemata oli teise vaktsineerimisega võrreldes reaktogeensus suurem esimese annuse järel.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
no increase in the reactogenicity was observed after the booster vaccination with respect to the primary vaccination.
korduva vaktsineerimise järgselt ei täheldatud reaktogeensuse suurenemist esmase vaktsineerimisega võrreldes.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
there was no evidence of an increased rate of reactogenicity or change in the safety profile of the vaccines in either study.
kummagi uuringu käigus ei täheldatud vaktsiinide reaktogeensuse tõusu ega muutusi ohutusprofiilis.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
a booster dose with tritanrix hepb will give rise to increased reactogenicity as would be expected for a booster during the second year of life.
tritanrix hepb lisaannus suurendab reaktogeensust, mida oodatakse revaktsineerimisest teisel eluaastal.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
reactogenicity after a third dose, administered 12 months after the second dose, was higher than after both first and second dose.
reaktogeensus pärast kolmandat annust, manustatuna 12 kuud pärast teist annust, oli suurem kui pärast nii esimest kui teist annust.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the reactogenicity profile of fendrix in a total of 82 pre-haemodialysis and haemodialysis patients was generally comparable to that seen in healthy subjects.
fendrixi reaktogeensus kokku 82 hemodialüüsi eelses seisundis ja hemodialüüsi saaval patsiendil oli üldiselt võrreldav tervete isikutega.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
the approval was based on results from clinical trials, which investigated the immunogenicity and reactogenicity of hexavac when administered according to specific primary and booster vaccination schedules.
heakskiit põhines kliinilistel uuringutel, milles uuriti hexavaci tekitatud immunogeensust ja reaktogeensust selle manustamisel konkreetsete esmase ja revaktsineerimise graafikute alusel.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
data in children and adolescents 3-17 years suggest a slight decrease in reactogenicity after the second dose, with no increase in rates of fever.
andmed lastel ja noorukitel vanuses 3 kuni 17 eluaastat viitavad kergele reaktogeensuse tõusule pärast teist annust, ilma palaviku esinemise suurenemiseta.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
safety and reactogenicity evaluations were performed for all subjects during the first 3 weeks following vaccination and saes have been collected for approximately 6700 vaccinees during six months of follow-up.
ohutust ja reaktogeensust hinnati kõikidel uuritavatel esimesel kolmel vaktsineerimisjärgsel nädalal ja tõsiste kõrvaltoimete kohta koguti andmeid ligikaudu 6700-l vaktsineeritul 6-kuulise jälgimisperioodi jooksul.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
as has been observed for dtpa and dtpa-containing combinations, an increase in local reactogenicity and fever was reported after booster vaccination with infanrix hexa with respect to the primary course.
nagu ka dtpa ja teiste dtpa-d sisaldavate vaktsiinide korral on täheldatud, ilmnes pärast revaktsineerimist infanrix hexa’ga lokaalse reaktogeensuse ja palaviku esinemissageduse tõus võrrelduna esmase vaktsineerimisega.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
data obtained with the h5n1 vaccines will support a vaccination strategy that is likely to be used for the pandemic vaccine: clinical immunogenicity, safety and reactogenicity data obtained with h5n1 vaccines are relevant for the pandemic and prepandemic vaccines.
h5n1 vaktsiinidega saadud andmete põhjal võib kasutada vaktsineerimisstrateegiat, mida tõenäoliselt kasutatakse pandeemiate korral: h5n1 vaktsiinide põhjal saadud kliinilise immunogeensuse, ohutuse ja reaktogeensuse andmed näitavad, et vaktsiin sobib kasutamiseks pandeemia ajal ja pandeemiaeelselt.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the administration of a second half adult or an adult dose did not enhance the reactogenicity, except for rates of general symptoms which were higher after the second dose, particularly for rates of fever in <6 year olds.
teise täiskasvanu poolannuse või teise täiskasvanu-annuse manustamine ei suurendanud reaktogeensust, välja arvatud üldsümptomite esinemissageduse osas, mis oli teise annuse manustamise järel kõrgem, eriti palaviku esinemissagedus <6aastastel lastel.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
data obtained with the mock-up vaccine will support a vaccination strategy that is likely to be used for the pandemic vaccine: clinical immunogenicity, safety and reactogenicity data obtained with mock-up vaccines are relevant for the pandemic vaccines.
imitatsioonvaktsiinidega saadav informatsioon toetab pandeemilise vaktsiini puhul rakendatavat strateegiat: imitatsioonvaktsiinidega saadud kliinilise immunogeensuse, ohutuse ja reaktogeensuse andmed laienevad pandeemilistele vaktsiinidele.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: